November 19, 2026 · Lancet (London, England) · DOI: 10.1016/S0140-6736(26)01562-X

Seasonal mass vaccination with R21/Matrix-M against malaria in The Gambia and Burkina Faso: an open-label, cluster-randomised, controlled trial.

Listen to this summary

This cluster-randomised trial asked whether seasonal mass vaccination with the R21/Matrix-M malaria vaccine, given before peak transmission, could reduce malaria infection prevalence and be safe in The Gambia (low-to-moderate transmission) and Burkina Faso (intense seasonal transmission). Across 54 villages, three monthly doses reduced the odds of P. falciparum infection at peak transmission by 70% in The Gambia (aOR 0.30) and by 25% in Burkina Faso (aOR 0.75), with the vaccine judged safe and well tolerated. The authors conclude that seasonal mass vaccination could be an additional malaria control strategy in seasonal transmission settings, though its effect was considerably larger in The Gambia than in Burkina Faso.

Edgard D Dabira, H Magloire Natama, Annette Erhart, Biébo Bihoun, Modou Lamin Keita, Karim Derra, Amadou Bah, Nafissatou Ilboudo, Mamadou O Ndiath, Massa Dit Achille Bonko, Lamin Saidy, Al Hassan Ilboudo, Miguel Hugues Olivier Kafando, Fatou Jaiteh, Fadima Y Bocoum, Koen Peeters Grietens, Balla Gibba, Sidzabda C B Kompaore, Adrian V S Hill, Lucy Okell, Azra Ghani, Nuredin I Mohammed, Halidou Tinto, Umberto D'Alessandro

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play